Daxor Corp Dossier
Qualitative Analysis
Business overview
Daxor Corporation (NASDAQ: DXR) is a medical instrumentation and biotechnology company focused on blood volume measurement. The company manufactures and distributes its patented, FDA-cleared Blood Volume Analyzer (BVA-100) and next-generation portable systems. Daxor's technology provides rapid, precise, and individualized blood volume data to guide treatment decisions in high-cost medical conditions such as heart failure and critical care. The company operates a state-of-the-art 20,000-square-foot manufacturing facility in Oak Ridge, Tennessee.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Transitioning the primary regulatory reporting framework from the Investment Company Act of 1940 back to the Securities Exchange Act of 1934, following the sale of all remaining investment portfolio positions in December 2025.
Expected impact: Reaffirms the company's sole focus on its core radiopharmaceutical blood volume operating business and removes investment company restrictions.
Bringing the manufacturing of Volumex, Megatope, and Glofil in-house to the company's 20,000-square-foot Oak Ridge, Tennessee facility.
Expected impact: Substantially increases gross margins on blood volume analysis (BVA) test kits and establishes internalized production control.
Development of a clinical decision support tool designed to precisely guide blood volume management and treatment in sepsis patients, supported by a $305K Phase I SBIR grant from the NIH.
Expected impact: Provides a rapid bedside test with a clinically validated sepsis fluid guidance support tool to address a multi-billion-dollar unmet clinical need.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquired exclusive, worldwide rights and intellectual property to manufacture Volumex and Megatope from its existing supplier, along with exclusive rights to Glofil (a drug measuring glomerular filtration rate). This allows Daxor to bring manufacturing in-house to its Oak Ridge facility, increasing margins on BVA test kits and adding a kidney function diagnostic to cross-sell to its hospital customer base.
Financial impact: Expected to be immediately cash flow positive and accretive to earnings upon completion of the manufacturing transfer due to higher internalized margins and embedded revenue streams.
Strategic Partnerships
Provides distribution channels to the federal healthcare marketplace, including the Department of Defense (DoD), Department of Veterans Affairs (VA), and Health and Human Services (HHS) to drive adoption of the BVA-100 system.
Terms: Not disclosed
Accelerates commercial adoption of Blood Volume Analysis by engaging directly with cardiovascular service line leaders and thought leaders within the MedAxiom network.
Terms: Not disclosed